Scorpius (HTBX) hit by $11.3M Q1 loss, delisting and looming cash crunch through Aug 2025

Scorpius Holdings, Inc. (NASDAQ: HTBX) - Quick read on what's happening inside

Short summary: the company is operating as a small CDMO but is cash‑constrained, has large recurring losses, recent lease and debt defaults, and was delisted from NYSE American (now trading on OTC Pink). Management is pursuing strategic alternatives and short‑term financings but faces substantial doubt about going concern.

Key facts & figures (Q1 2025 and related)
* Revenue: $212,264 (Q1 2025) vs $3,513,948 (Q1 2024).
* Net loss: $(11,288,126) (total); net loss attributable to Scorpius: $(10,714,555).
* Net loss per share, basic & diluted: $(1.16) (weighted‑average shares 9,220,185).
* Cash and cash equivalents: $188,914; short‑term investments: $60,248 - cash + ST investments ≈ $249,162 (Mar 31, 2025).
* Total current assets: $2,040,078; total assets: $23,585,574.
* Total liabilities: $30,148,342; total stockholders' (deficit) equity: $(6,562,768).
* Accumulated deficit: $(297,893,225).
* Net cash used in operating activities (Q1 2025): $(3,371,660).
* Lease losses and asset disposals: loss on lease assignment $1,600,531; loss on lease termination $4,132,767; loss on disposal of long‑lived assets $721,564.
* Debt / fair values (Mar 31, 2025): convertible promissory notes, related party - $12,043,000 (FV); non‑convertible promissory notes, related party - $1,390,000 (FV); December 2024 Secured Convertible Notes outstanding balance (incl. accrued interest & make‑whole): $14,994,810 (Mar 31, 2025 & Aug 22, 2025).
* 2025 non‑convertible promissory notes outstanding principal: $5,790,000 (as of Aug 22, 2025).
* Revenue concentration: one customer = 98% of Q1 2025 revenue; two customers = 77% of Q1 2024 revenue (one large customer migrated in 2024).
* Corporate actions: delisted from NYSE American (April-May 2025), trading on OTC Pink; engaged Alliance Global Partners to explore strategic alternatives; private placement first tranche received $1,942,650 net (Apr 28, 2025).

Positive takeaways
* The business has operating revenue from CDMO services (not zero) and recognized some grant revenue (NIH: $12,000 in Q1 2025).
* Management is actively raising capital (convertible and non‑convertible notes, private placement tranche) and pursuing strategic alternatives (engaged advisor).
* R&D and SG&A were reduced versus prior year quarter (R&D down ~$0.7M; SG&A down ~$1.0M), indicating cost‑cutting efforts.

Negative / risks from the income statement and notes
* Revenue collapse: revenue fell from $3.51M to $0.21M year‑over‑year - severe top‑line deterioration.
* Large recurring loss: $11.3M net loss in one quarter, driven by operating losses plus substantial non‑operating lease and disposal charges.
* One‑time and recurring noncash volatility: large fair‑value swings on related‑party notes, warrant liability and contingent receivables materially move non‑operating income/expense.
* Lease disruption: $4.13M loss from manufacturing lease termination - operational disruption and potential loss of manufacturing capacity.
* Debt stress: defaults noted (2025 non‑convertible related‑party notes defaulted; missed quarterly interest payments on secured convertible notes as of Aug 22, 2025) and secured notes grant lenders sweeping rights and collateral.
* Customer concentration: one customer accounted for 98% of revenue in Q1 2025 - high customer risk.
* Going concern & limited runway: company discloses substantial doubt; cash runway reported sufficient only through August 2025 absent new financing.
* Controls & governance: multiple material weaknesses in internal control over financial reporting remain unremediated (IT access, revenue recognition, impairment reviews, tax accounting).
* Market access: delisting from NYSE American limits visibility and may hamper future financing options.

What to watch next (near term)
* Cash inflows / financing: new closings of private placement tranches, equity raises, or strategic partner that extend runway beyond Aug 2025.
* Debt holder actions: any acceleration, foreclosure, or forced redemptions related to secured convertible notes or non‑convertible notes.
* Lease resolution and manufacturing continuity: outcome of San Antonio lease termination and operational impact on CDMO revenue generation.
* Customer diversification: evidence of new contracts beyond the single dominant customer.
* Remediation of internal control weaknesses and timely SEC filings to regain better market access.

Bottom line: Scorpius (NASDAQ: HTBX) is a small CDMO with real operations but acute liquidity, operational and governance problems. The Q1 2025 income statement shows minimal revenue, a large quarterly loss driven by both operating shortfalls and significant one‑time lease/debt adjustments, and heavy dependence on financings and related‑party debt. Investors should treat current equity as high risk - key determinants in the next 30-90 days will be cash raises, creditor forbearance or strategic transactions and resolution of the lease/default issues.